Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.

× No keyword cloud information.

19 in total

1. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.

Authors: Shao-Bo Ke; Hu Qiu; Jia-Mei Chen; Wei Shi; Yong-Shun Chen
Journal: Curr Med Sci Date: 2018-12-07

2. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).

Authors: Shunjun Jiang; Hengrui Liang; Zhichao Liu; Shen Zhao; Jun Liu; Zhanhong Xie; Wei Wang; Yalei Zhang; Baohui Han; Jianxing He; Wenhua Liang
Journal: Oncologist Date: 2020-02-20

3. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.

Authors: SooYoon Sung; Sea-Won Lee; Yoo-Kang Kwak; Jin Hyung Kang; Sook Hee Hong; Yeon-Sil Kim
Journal: J Neurooncol Date: 2018-04-11 Impact factor: 4.130

4. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.

Authors: Kai Dong; Wenhua Liang; Shen Zhao; Minzhang Guo; Qihua He; Caichen Li; Haiqing Song; Jianxing He; Xiaojun Xia
Journal: Transl Lung Cancer Res Date: 2019-06

5. The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients.

Authors: Vanita Noronha; Amit Joshi; Anant Gokarn; Vibhor Sharma; Vijay Patil; Amit Janu; Nilendu Purandare; Anuradha Chougule; Nirmala Jambhekar; Kumar Prabhash
Journal: Chemother Res Pract Date: 2014-12-07

Review 6. Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

Authors: Bryan Oronsky; Patrick Ma; Tony R Reid; Pedro Cabrales; Michelle Lybeck; Arnold Oronsky; Neil Oronsky; Corey A Carter
Journal: Neoplasia Date: 2017-12-08 Impact factor: 5.715

7. Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer.

Authors: Vijaya Raj Bhatt; Sanyo P D'Souza; Lynette M Smith; Allison M Cushman-Vokoun; Vanita Noronha; Vivek Verma; Amit Joshi; Anuradha Chougule; Nirmala Jambhekar; Anne Kessinger; Alissa Marr; Vijay Patil; Sripad D Banavali; Apar Kishor Ganti; Kumar Prabhash
Journal: J Glob Oncol Date: 2016-07-20

8. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

Authors: Bob T Li; Emil Lou; Meier Hsu; Helena A Yu; Jarushka Naidoo; Marjorie G Zauderer; Camelia Sima; Melissa L Johnson; Mariza Daras; Lisa M DeAngelis; Martin Fleisher; Mark G Kris; Christopher G Azzoli
Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240

9. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Authors: Yongshun Chen; Jing Yang; Xue Li; Daxuan Hao; Xiaoyuan Wu; Yuanyuan Yang; Chunyu He; Wen Wang; Jianhua Wang
Journal: Cancer Sci Date: 2016-11-25 Impact factor: 6.716

Review 10. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.

Authors: Matthias Preusser; Frank Winkler; Manuel Valiente; Christian Manegold; Elizabeth Moyal; Georg Widhalm; Jörg-Christian Tonn; Christoph Zielinski
Journal: ESMO Open Date: 2018-01-26